Cargando...
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
Introduction: Major depressive disorder (MDD) is the leading cause of disability worldwide, and according to the STAR*D trial, only 33% of patients with MDD responded to initial drug therapy. Augmentation of the leading class of antidepressant treatment, selective serotonin reuptake inhibitors (SSRI...
Guardado en:
| Publicado en: | Expert Opin Drug Discov |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4841022/ https://ncbi.nlm.nih.gov/pubmed/26971593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/17460441.2016.1160051 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|